Epigenetics and novel signaling pathways in prostate carcinogenesis
Poster Session 07
-
Location:Room Amsterdam, North Hall (Level 1)
-
Chairs:
-
Aims and objectives of this session Invasion and metastasis in prostate cancer are regulated by different signaling molecules. In this session, the pathway of Wnt/beta-catenin and its interaction with other signaling cascased in prostate tumorigenesis and progression will be highlighted. In addition, novel findings about regulation of the key transcription factor ERG will be presented.
- Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
Institutes: 1IOR Institute of Oncology Research, Tumor Biology and Experimental Therapeutic, Bellinzona, Switzerland, 2University of Bern, Inselspital, Dept. of Urology, Bern, Switzerland, 3Fondo Edo Tempia, Laboratory of Cancer Genomics, Biella, Italy
Institutes: 1University Hospital Mainz, Dept. of Urology, Mainz, Germany, 2Heidelberg Institute for Stem Cell Technology and Experimental Medicine, HI-STEM GGmbH, Heidelberg, Germany
Institutes: 1Chang Gung University, Dept. of Anatomy, Tao-yuan, Kwei-shan, Taiwan, 2Chang Gung Memorial Hospital, Dept. of Urology, Tao-yuan, Kwei-shan, Taiwan
Institutes: 1Brody School Of Medicine At East Carolina University, Dept. of Anatomy and Cell Biology, Greenville, United States of America, 2Brody School Of Medicine At East Carolina University, Dept. of Anatomy And Cell Biology, Greenville, United States of America, 3Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing An Zhen Hospital, Capital Medical University, Beijing, China, 4Beijing An Zhen Hospital, Capital Medical University, Dept. of Urology, Beijing, China, 5PLA Army General Hospital, Dept. of Urology, Beijing, China, 6Southeast University School of Clinical Medicine, Dept. of Hematology and Oncology, Nanjing, China
Institutes: 1University of Tübingen, Dept. of Urology, Tübingen, Germany, 2University of Tübingen, Dept. of Immunology, Tübingen, Germany, 3Boehringer Ingelheim RCV GmgH & CoKG, NBE Discovery, Vienna, Austria
Institutes: 1Bradford Royal Infirmary, Dept. of Urology, Bradford, United Kingdom, 2British Columbia Cancer Research Centre, Proteomics Unit, Vancouver, Canada, 3Vancouver Prostate Centre, Tumour Biology Group, Vancouver, Canada, 4Vancouver Prostate Centre, Bioinformatics Group, Vancouver, Canada, 5University of British Columbia, Dept. of Urological Sciences, Vancouver, Canada, 6University of British Columbia, Dept. of Pathology & Laboratory Medicine, Vancouver, Canada
Institutes: 1KU Leuven, Molecular Endocrinology Laboratory, Leuven, Belgium, 2Institute of Biomedicine of The University of Barcelona, Dept. of Biochemistry and Molecular Biomedicine, Barcelona, Spain, 3Parc Cientific De Barcelona, Mass Spectrometry Core Facility, Barcelona, Spain, 4Centres Cientifics I Tecnologics, Unitat De Citometra, Barcelona, Spain, 5Erasmus MC, Dept. of Pathology, Rotterdam, The Netherlands
Institutes: 1University of Oxford, Dept. of Physiology, Anatomy and Genetics, Oxford, United Kingdom, 2University of Oxford, The Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Oxford, United Kingdom, 3University of Oxford, Nuffield Department of Surgical Sciences, John Radcliffe Hospital, Oxford, United Kingdom